These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 25307179)
1. Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia. Pieri L; Guglielmelli P; Vannucchi AM Am J Hematol; 2015 Jan; 90(1):82-3. PubMed ID: 25307179 [No Abstract] [Full Text] [Related]
2. Topical Ruxolitinib for the Treatment of Alopecia Universalis. Craiglow BG; Tavares D; King BA JAMA Dermatol; 2016 Apr; 152(4):490-1. PubMed ID: 26649829 [No Abstract] [Full Text] [Related]
3. Two cases of alopecia areata treated with ruxolitinib: a discussion of ideal dosing and laboratory monitoring. Vandiver A; Girardi N; Alhariri J; Garza LA Int J Dermatol; 2017 Aug; 56(8):833-835. PubMed ID: 28322434 [TBL] [Abstract][Full Text] [Related]
4. Alopecia Universalis and Chronic Graft-vs-Host Disease Treated With Ruxolitinib. Borg MA; Shalabi RA; Childs R; Wells BC JAMA Dermatol; 2018 Nov; 154(11):1357-1358. PubMed ID: 30285060 [No Abstract] [Full Text] [Related]
5. Hepatitis B virus reactivation associated with ruxolitinib. Shen CH; Hwang CE; Chen YY; Chen CC Ann Hematol; 2014 Jun; 93(6):1075-6. PubMed ID: 24173089 [No Abstract] [Full Text] [Related]
7. Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study. Almutairi N; Nour TM; Hussain NH Dermatology; 2019; 235(2):130-136. PubMed ID: 30566941 [TBL] [Abstract][Full Text] [Related]
8. The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib. O'Sullivan JM; Hamblin A; Yap C; Fox S; Boucher R; Panchal A; Alimam S; Dreau H; Howard K; Ware P; Cross NCP; McMullin MF; Harrison CN; Mead AJ Blood; 2019 Dec; 134(23):2107-2111. PubMed ID: 31578205 [TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetic analysis of orally-administered ruxolitinib (INCB018424 Phosphate) in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET MF). Chen X; Williams WV; Sandor V; Yeleswaram S J Clin Pharmacol; 2013 Jul; 53(7):721-30. PubMed ID: 23677817 [TBL] [Abstract][Full Text] [Related]
10. Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study Palandri F; Palumbo GA; Iurlo A; Polverelli N; Benevolo G; Breccia M; Abruzzese E; Tiribelli M; Bonifacio M; Tieghi A; Isidori A; Martino B; Sgherza N; D'Adda M; Bergamaschi M; Crugnola M; Cavazzini F; Bosi C; Binotto G; Auteri G; Latagliata R; Ibatici A; Scaffidi L; Penna D; Cattaneo D; Soci F; Trawinska M; Russo D; Cuneo A; Semenzato G; Di Raimondo F; Aversa F; Lemoli RM; Heidel F; Reggiani MLB; Bartoletti D; Cavo M; Catani L; Vianelli N Semin Hematol; 2018 Oct; 55(4):248-255. PubMed ID: 30502854 [TBL] [Abstract][Full Text] [Related]
11. Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results. Verstovsek S; Passamonti F; Rambaldi A; Barosi G; Rumi E; Gattoni E; Pieri L; Zhen H; Granier M; Assad A; Cazzola M; Kantarjian HM; Barbui T; Vannucchi AM Blood; 2017 Oct; 130(15):1768-1771. PubMed ID: 28827411 [No Abstract] [Full Text] [Related]
12. JAK2 inhibitors for myeloproliferative neoplasms: what is next? Bose P; Verstovsek S Blood; 2017 Jul; 130(2):115-125. PubMed ID: 28500170 [TBL] [Abstract][Full Text] [Related]
13. A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post--polycythemia vera/essential thrombocythemia myelofibrosis (post--PV/ET MF). Mascarenhas J; Marcellino BK; Lu M; Kremyanskaya M; Fabris F; Sandy L; Mehrotra M; Houldsworth J; Najfeld V; El Jamal S; Petersen B; Moshier E; Hoffman R Leuk Res; 2020 Jan; 88():106272. PubMed ID: 31778911 [TBL] [Abstract][Full Text] [Related]
14. Treatment of alopecia universalis with topical Janus kinase inhibitors - a double blind, placebo, and active controlled pilot study. Bokhari L; Sinclair R Int J Dermatol; 2018 Dec; 57(12):1464-1470. PubMed ID: 30160787 [TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms. Pieri L; Paoli C; Arena U; Marra F; Mori F; Zucchini M; Colagrande S; Castellani A; Masciulli A; Rosti V; De Stefano V; Betti S; Finazzi G; Ferrari ML; Rumi E; Ruggeri M; Nichele I; Guglielmelli P; Fjerza R; Mannarelli C; Fanelli T; Merli L; Corbizi Fattori G; Massa M; Cimino G; Rambaldi A; Barosi G; Cazzola M; Barbui T; Vannucchi AM Am J Hematol; 2017 Feb; 92(2):187-195. PubMed ID: 27880982 [TBL] [Abstract][Full Text] [Related]
16. Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. Harrison CN; Mead AJ; Panchal A; Fox S; Yap C; Gbandi E; Houlton A; Alimam S; Ewing J; Wood M; Chen F; Coppell J; Panoskaltsis N; Knapper S; Ali S; Hamblin A; Scherber R; Dueck AC; Cross NCP; Mesa R; McMullin MF Blood; 2017 Oct; 130(17):1889-1897. PubMed ID: 29074595 [TBL] [Abstract][Full Text] [Related]
17. Drug Development Pipeline for Myeloproliferative Neoplasms: Potential Future Impact on Guidelines and Management. Bose P; Verstovsek S J Natl Compr Canc Netw; 2016 Dec; 14(12):1613-1624. PubMed ID: 27956543 [TBL] [Abstract][Full Text] [Related]